NASDAQ:ENDP - Endo International Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $8.33 -0.43 (-4.91 %) (As of 03/22/2019 04:00 PM ET)Previous Close$8.76Today's Range$8.18 - $8.7852-Week Range$5.27 - $18.50Volume3.52 million shsAverage Volume3.39 million shsMarket Capitalization$1.87 billionP/E Ratio2.88Dividend YieldN/ABeta1.21 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals. The U.S. Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, abuse-deterrent products, liquids, semi-solids, patches, powders, ophthalmics, sprays, and sterile injectables, as well as products for the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health, and cardiovascular disease markets. The U.S. Branded Pharmaceuticals segment provides XIAFLEX for the treatment of Dupuytren's contracture and Peyronie's diseases; SUPPRELIN LA for central precocious puberty treatment; TESTOPEL, a long-acting implantable pellet for the treatment of central precocious puberty; NASCOBAL, a nasal spray to treat vitamin B12 deficiency; and AVEED for the treatment of hypogonadism. This segment also offers pain management products, such as PERCOCET, VOLTAREN Gel, and LIDODERM; TESTIM Gel for the treatment of endogenous testosterone; and FORTESTA Gel for hypogonadism treatment. The International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, and oncology. It sells its branded pharmaceuticals and generics directly to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors, as well as through wholesale drug distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland. Receive ENDP News and Ratings via Email Sign-up to receive the latest news and ratings for ENDP and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:ENDP Previous Symbol CUSIP29264F20 CIK1593034 Webwww.endo.com Phone011-353-1268-2000Debt Debt-to-Equity RatioN/A Current Ratio1.20 Quick Ratio1.04Price-To-Earnings Trailing P/E Ratio2.88 Forward P/E Ratio3.84 P/E GrowthN/A Sales & Book Value Annual Sales$2.95 billion Price / Sales0.63 Cash Flow$5.9928 per share Price / Cash Flow1.39 Book Value($2.22) per share Price / Book-3.75Profitability EPS (Most Recent Fiscal Year)$2.89 Net Income$-1,031,470,000.00 Net Margins-35.00% Return on Equity-337.13% Return on Assets6.25%Miscellaneous Employees2,910 Outstanding Shares224,404,000Market Cap$1.87 billion Next Earnings Date5/14/2019 (Estimated) OptionableOptionable Endo International (NASDAQ:ENDP) Frequently Asked Questions What is Endo International's stock symbol? Endo International trades on the NASDAQ under the ticker symbol "ENDP." How were Endo International's earnings last quarter? Endo International PLC (NASDAQ:ENDP) announced its earnings results on Thursday, February, 28th. The company reported $0.75 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.59 by $0.16. Endo International had a negative return on equity of 337.13% and a negative net margin of 35.00%. During the same period in the previous year, the firm posted $0.77 earnings per share. View Endo International's Earnings History. When is Endo International's next earnings date? Endo International is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for Endo International. What guidance has Endo International issued on next quarter's earnings? Endo International issued an update on its FY19 earnings guidance on Thursday, February, 28th. The company provided earnings per share guidance of $2.00-2.25 for the period, compared to the Thomson Reuters consensus estimate of $2.66. The company issued revenue guidance of $2.76-2.96 billion, compared to the consensus revenue estimate of $2.92 billion.Endo International also updated its FY 2019 guidance to $2.00-2.25 EPS. What price target have analysts set for ENDP? 18 brokerages have issued 1 year price objectives for Endo International's shares. Their predictions range from $9.00 to $26.00. On average, they anticipate Endo International's stock price to reach $15.7333 in the next year. This suggests a possible upside of 88.9% from the stock's current price. View Analyst Price Targets for Endo International. What is the consensus analysts' recommendation for Endo International? 18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Endo International in the last year. There are currently 12 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Endo International. What are Wall Street analysts saying about Endo International stock? Here are some recent quotes from research analysts about Endo International stock: 1. According to Zacks Investment Research, "Endo is in the process of redefining its business, given the persistent decline in the generic business which is facing challenges. The focus now is on sterile injectables and Xiaflex. Demand for Xiaflex continues to be strong owing to high demand driven by increased demand in both Peyronie's disease and Dupuytren's contracture. Moreover, Endo has centralized and streamlined its global supply chain, quality and compliance organization in order to create a more cohesive and efficient structure to support both its generics and branded businesses. Endo is working to expand the drug’s label. However, huge level of debt is a concern. Moreover, response rates from the CCH trials weren’t impressive either. Estimates for Q4 are down by a cent in the last 30 days." (2/26/2019) 2. Canaccord Genuity analysts commented, "We view Athenex’s compounded vasopressin launch today as more headline risk than an actual financial hit to Endo’s near-term results. We expect Endo to restart litigation with FDA regarding compounding guidance and we’d also expect patent litigation against Athenex that could potentially enjoin sales of the compounded product. While ENDP shares have had strong momentum of late, we remain concerned that little events like these – along with broader opioid and product litigation – could dent that momentum. As such, we maintain our HOLD rating on ENDP shares." (8/13/2018) Has Endo International been receiving favorable news coverage? News articles about ENDP stock have trended somewhat positive recently, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Endo International earned a media sentiment score of 0.9 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an impact on the stock's share price in the next few days. Who are some of Endo International's key competitors? Some companies that are related to Endo International include Jazz Pharmaceuticals (JAZZ), SAGE Therapeutics (SAGE), Loxo Oncology (LOXO), Dr.Reddy's Laboratories (RDY), Perrigo (PRGO), Marina Biotech (MRNA), Catalent (CTLT), Amarin (AMRN), Nektar Therapeutics (NKTR), Alkermes (ALKS), United Therapeutics (UTHR), GALAPAGOS NV/S (GLPG), GW Pharmaceuticals PLC- (GWPH), Ascendis Pharma A/S (ASND) and Array Biopharma (ARRY). What other stocks do shareholders of Endo International own? Based on aggregate information from My MarketBeat watchlists, some companies that other Endo International investors own include Bausch Health Companies (BHC), General Electric (GE), Micron Technology (MU), Gilead Sciences (GILD), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Teva Pharmaceutical Industries (TEVA), Twitter (TWTR) and Bank of America (BAC). Who are Endo International's key executives? Endo International's management team includes the folowing people: Mr. Paul V. Campanelli, Pres, CEO & Director (Age 57)Mr. Blaise Coleman, Exec. VP & CFO (Age 45)Mr. Terrance J. Coughlin, Exec. VP & COO (Age 53)Mr. Matthew Joseph Maletta, Exec. VP & Chief Legal Officer (Age 47)Mr. Antonio R. Pera, Pres of Par Pharmaceutical (Age 62) Who are Endo International's major shareholders? Endo International's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Norges Bank (1.30%), Bank of New York Mellon Corp (1.13%), Geode Capital Management LLC (1.09%), Geode Capital Management LLC (1.09%), Connor Clark & Lunn Investment Management Ltd. (0.68%) and Diamond Hill Capital Management Inc. (0.58%). Company insiders that own Endo International stock include Blaise Coleman, Matthew Joseph Maletta, Nancy J Hutson, Paul Campanelli, Roger H Kimmel, Terrance J Coughlin and William P Montague. View Institutional Ownership Trends for Endo International. Which major investors are selling Endo International stock? ENDP stock was sold by a variety of institutional investors in the last quarter, including Tekla Capital Management LLC, River & Mercantile Asset Management LLP, Commonwealth Bank of Australia, Geode Capital Management LLC, Geode Capital Management LLC, Gabelli Funds LLC, New York State Teachers Retirement System and Connor Clark & Lunn Investment Management Ltd.. Company insiders that have sold Endo International company stock in the last year include Nancy J Hutson, Roger H Kimmel and William P Montague. View Insider Buying and Selling for Endo International. Which major investors are buying Endo International stock? ENDP stock was purchased by a variety of institutional investors in the last quarter, including Norges Bank, Canada Pension Plan Investment Board, Oregon Public Employees Retirement Fund, Diamond Hill Capital Management Inc., Bowling Portfolio Management LLC, Rhumbline Advisers, Oregon Public Employees Retirement Fund and LMR Partners LLP. Company insiders that have bought Endo International stock in the last two years include Blaise Coleman, Matthew Joseph Maletta, Paul Campanelli and Terrance J Coughlin. View Insider Buying and Selling for Endo International. How do I buy shares of Endo International? Shares of ENDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Endo International's stock price today? One share of ENDP stock can currently be purchased for approximately $8.33. How big of a company is Endo International? Endo International has a market capitalization of $1.87 billion and generates $2.95 billion in revenue each year. The company earns $-1,031,470,000.00 in net income (profit) each year or $2.89 on an earnings per share basis. Endo International employs 2,910 workers across the globe. What is Endo International's official website? The official website for Endo International is http://www.endo.com. How can I contact Endo International? Endo International's mailing address is First Floor Minerva House Simmonscourt Road Ballsbridge, Dublin L2, 19355. The company can be reached via phone at 011-353-1268-2000 or via email at [email protected] MarketBeat Community Rating for Endo International (NASDAQ ENDP)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 853 (Vote Outperform)Underperform Votes: 706 (Vote Underperform)Total Votes: 1,559MarketBeat's community ratings are surveys of what our community members think about Endo International and other stocks. Vote "Outperform" if you believe ENDP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENDP will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/23/2019 by MarketBeat.com StaffFeatured Article: Dividend Stocks - Are They Right For You?